Navigation Links
Novavax Prices Public Offering of Common Stock
Date:11/20/2009

ROCKVILLE, Md., Nov. 20 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it has priced an underwritten public offering of 6,800,000 shares of its common stock at a price to the public of $3.30 per share. The approximately $21 million of net proceeds, after deducting the underwriting discounts and commissions, will be used for preclinical studies and clinical trials of our VLP-based vaccines, internal research and development programs, working capital, capital expenditures and other general corporate purposes. The offering is expected to close on or about November 25, 2009, subject to the satisfaction of customary closing conditions.

Piper Jaffray & Co. and Lazard Capital Markets LLC are acting as joint book running managers. The offering is being made pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained from the Securities and Exchange Commission at http://www.sec.gov or from Piper Jaffray & Co. at 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402 or by calling 1-800-747-3924.

The underwriters have been granted an option to purchase up to an additional 1,020,000 shares at any time on or prior to December 8, 2009 to cover over-allotments, if any.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, of the securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Novavax

Novavax, Inc. is a clinical-st
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Novavax CEO to Present at BIO CEO & Investor Conference
2. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
3. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
4. Novavax CEO to Present at the World Vaccine Congress 2008
5. Novavax Opens Its First U.S. Vaccine Plant
6. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
7. Novavax Reports First Quarter 2008 Financial Results
8. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
9. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
10. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
11. Novavax to Join Russell 3000 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... WA (PRWEB) March 02, 2015 Sterlitech ... flow flat-sheet testing system at the 2015 AMTA Membrane ... a culmination of a decade’s worth of engineering and ... compatible with a wide range of applications across an ... versatile enough to meet the dynamic needs of researchers ...
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... has been made aware of a fraudulent press release ... GlobeNewswire, purporting to be from Immunovaccine. This press release ... with Gilead Science, Inc. The press release did ... to the information contained within the press release. ...
(Date:2/27/2015)... Nova Scotia (PRWEB) February 27, 2015 ... stage vaccine and immunotherapy company, today announced that ... its application for Fast Track designation and Phase ... vaccines, in conjunction with the mutual co-development agreement ... previously obtained Fast Track designation for the DPX-Survivac. ...
(Date:2/27/2015)... CA (PRWEB) February 27, 2015 Cytokinetics, ... forces on February 28 with patients and health care ... awareness for Rare Disease Day®. Rare Disease Day ... and calling attention to the special challenges faced by ... them. , “Cytokinetics is proud to stand alongside patients ...
Breaking Biology Technology:Sterlitech Displays Complete CF042 Membrane Test System 2Immunovaccine Disclaims Hoax Press Release 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6
... 16 Monogram,Biosciences, Inc. (Nasdaq: MGRM ) ... of the company,s HIV tropism assay were presented ... Drug Resistance Workshop,in Sitges, Spain. Trofile was introduced ... in class CCR5 antagonist, in,August 2007. Recent enhancements ...
... /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc.,(TSX: PLI) ... compound in clinical trial in patients with ... the European Hematology Association,held in Copenhagen, Denmark ... Director R&D, Biology, presented data on,PBI-1402 in ...
... Inc. (Nasdaq: ALXN ) today announced that ... of Alexion,Pharmaceuticals, will present at the William Blair ... a.m., local time (10:10 a.m., eastern) on,Thursday, June ... Sinha,s remarks will be available live. You can,access ...
Cached Biology Technology:Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy 2Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy 3Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy 4Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy 5Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy 6Positive clinical data for PBI-1402 presented at the Annual Congress of the European Hematology Association 2Positive clinical data for PBI-1402 presented at the Annual Congress of the European Hematology Association 3
(Date:2/12/2015)... Conn. , Feb. 12, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... has filed provisional patent 62/113114 for DISTRIBUTED ... DEVICES. The patent further establishes NXT-ID,s position ... its intellectual property portfolio the ability for multiple devices ...
(Date:2/5/2015)... TRIANGLE PARK, N.C. , Feb. 5, 2015 /PRNewswire/ ... a specialist logistics company and has launched a new ... only Clinical Logistics Organization (CLO).  The new campaign focuses ... emphasis on patient, protocol and shipments. The ... First , aligns Marken,s priorities with its client,s ...
(Date:2/5/2015)... OXFORD, Conn. , Jan. 28, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... present at the upcoming RedChip Global Online CEO Conference ... Gino Pereira , CEO of ... discussing its lead product, the Wocket smart wallet and ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3
... This news release is available in French . ... of the administration and dosage of antipsychotics may influence their ... universitaire en sant mentale de Montral and Universit de Montral. ... their ability to get into the bloodstream after being absorbed. ...
... 8, 2013) According to Gertrude Stein, "A rose is ... might not be the case when it comes to the ... have found that as much as 30 percent of the ... individuals. This substantial variation is in turn reflected by variability ...
... in Lyon, a French city famed for its cuisine, have ... The breakthrough suggests a better way of producing the ... a few decades, it could even help the world meet ... greenhouse effect and climate change. It also ...
Cached Biology News:How can we improve the efficacy of antipsychotics in the era of personalized pharmacotherapy? 2Extensive variability in olfactory receptors influences human odor perception 2Deep Carbon Observatory scientists discover quick recipe for producing hydrogen 2Deep Carbon Observatory scientists discover quick recipe for producing hydrogen 3Deep Carbon Observatory scientists discover quick recipe for producing hydrogen 4Deep Carbon Observatory scientists discover quick recipe for producing hydrogen 5Deep Carbon Observatory scientists discover quick recipe for producing hydrogen 6
... Plus accurately and conveniently controls the temperature at ... different temperature levels up to 99 C*, with ... as low as 5 C. The thermoblocks for ... tubes, and microplates enable a high degree of ...
... developed to significantly increase the shelf life ... is increased at room temperature storage conditions ... product is subjected to 0.2 micron filtration, ... This formulation insures consistently high levels of ...
...
These 25x25 square No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick. • Approx. Pcs Oz : 102...
Biology Products: